Cardioloxía
Servizo
Duke Clinical Research Institute
Durham, Estados UnidosPublicacións en colaboración con investigadores/as de Duke Clinical Research Institute (24)
2023
-
Impact of Complete Revascularization in the ISCHEMIA Trial
Journal of the American College of Cardiology, Vol. 82, Núm. 12, pp. 1175-1188
-
Survival after Invasive or Conservative Management of Stable Coronary Disease
Circulation, Vol. 147, Núm. 1, pp. 8-19
2022
-
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
Circulation, Vol. 146, Núm. 16, pp. 1196-1206
-
Assessment of Omecamtiv Mecarbil for the Treatment of Patients with Severe Heart Failure: A Post Hoc Analysis of Data from the GALACTIC-HF Randomized Clinical Trial
JAMA Cardiology, Vol. 7, Núm. 1, pp. 26-34
-
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial
American Heart Journal, Vol. 248, pp. 72-83
-
Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial
European heart journal, Vol. 43, Núm. 2, pp. 148-149
-
Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry
Heart Rhythm, Vol. 19, Núm. 2, pp. 228-234
-
Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial
Circulation: Cardiovascular Interventions, Vol. 15, Núm. 4, pp. E010925
-
Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial
Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661
2021
-
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116
-
Comparison of Days Alive out of Hospital with Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial
JAMA Cardiology, Vol. 6, Núm. 9, pp. 1023-1031
2020
-
Initial invasive or conservative strategy for stable coronary disease
New England Journal of Medicine, Vol. 382, Núm. 15, pp. 1395-1407
2019
-
Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation: A Report from the GARFIELD-AF Registry
JAMA Cardiology, Vol. 4, Núm. 6, pp. 526-548
-
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
American Heart Journal, Vol. 213, pp. 35-46
-
Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry
Clinical Cardiology, Vol. 42, Núm. 5, pp. 553-560
2018
-
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529
-
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry
European Heart Journal, Vol. 39, Núm. 6, pp. 464-473
-
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
PLoS ONE, Vol. 13, Núm. 1
-
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
Indian Heart Journal, Vol. 70, Núm. 6, pp. 828-835